PuSH - Publikationsserver des Helmholtz Zentrums München

Fichtner, M.L.* ; Rübsamen, H.* ; Smolle, M.* ; Schaller, J.* ; Feederle, R. ; Bültmann, A.* ; Kümpfel, T.* ; Schneider, P.* ; Thaler, F.S.* ; Meinl, E.*

Features of isoforms of human soluble TACI.

J. Immunol. 211, 199-208 (2023)
Verlagsversion DOI PMC
Closed
Creative Commons Lizenzvertrag
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The BAFF/APRIL-system with the two cytokines BAFF and APRIL and their three receptors, transmembrane activator and CAML interactor (TACI), BAFF receptor, and B-cell maturation Ag, is important for B cell maintenance. The BAFF/APRIL system is a therapeutic target in B cell-derived malignancies and autoimmune diseases. However, unexpected outcomes of clinical trials with atacicept (TACI-Fc) underline our incomplete understanding of this system. Shedding of the three receptors is one important regulatory element. In humans, TACI exists in two isoforms generated through alternative splicing in their extracellular portion: TACI-long (l) has two cysteine-rich domains, whereas TACI-short (s) lacks the first low-affinity one. In this study, we discriminated soluble (s) forms of TACI-l and TACI-s with newly generated mAbs and found that both were spontaneously released from activated human B cells, with a predominance of sTACI-l. Furthermore, sTACI-l was also the dominant isoform in human serum. Vaccination with the mRNA vaccine from BioNTech does not significantly affect the serum levels of sTACI-l. Both TACI-s and TACI-l were shed by a disintegrin and metalloproteinase domain-containing protein 10. TACI-l and TACI-s formed homo- and hetero-oligomers in soluble and membrane-bound forms. Both sTACI-l and sTACI-s acted as decoy receptors for BAFF, but only sTACI-l also efficiently inhibited APRIL. Dimerization of sTACI-l enhanced its decoy functions only slightly. Together, we extend our knowledge of the complexity of the BAFF/APRIL system by identifying and characterizing the two soluble isoforms of TACI.
Impact Factor
Scopus SNIP
Altmetric
4.400
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Common Variable Immunodeficiency; Crystal-structure; Receptor; April; Baff; Bcma; Immunoregulator; Therapy; Antigen; System
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0022-1767
e-ISSN 1550-6606
Zeitschrift Journal of Immunology
Quellenangaben Band: 211, Heft: 2, Seiten: 199-208 Artikelnummer: , Supplement: ,
Verlag American Association of Immunologists
Verlagsort 9650 Rockville Pike, Bethesda, Md 20814 Usa
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-502210-001
Förderungen Deutsche Forschungsgemeinschaft research fellowship
Swiss National Science Foundation
Munich Cluster for Systems Neurology (SyNergy)
Else-Kroner Fresenius Stiftung
Gemeinnutzige Hertie Stiftung
Novartis Pharma
Merck
Deutsche Forschungsgemeinschaft
Scopus ID 85164209631
PubMed ID 37272840
Erfassungsdatum 2023-10-06